Clearmind Medicine shares are trading higher after the company announced successful completion of treatment and follow-up of 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the company's oral drug candidate for the treatment of Alcohol Use Disorder.